Positive Phase III data for tislelizumab in the first-line treatment of non-squamous non-small cell lung cancer presented at conference

In RATIONALE 304 (n=334), tislelizumab (200mg every 3 weeks) plus chemotherapy (pemetrexed plus platinum) was associated with longer progression-free survival than chemotherapy alone (median 9.7 v 7.6 months; HR 0.65; 95% CI 0.46-0.90; p=0.0044).


Biospace Inc.